Bank of New Hampshire Sells 443 Shares of Danaher Co. (NYSE:DHR)

Bank of New Hampshire decreased its stake in shares of Danaher Co. (NYSE:DHR) by 8.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,921 shares of the conglomerate’s stock after selling 443 shares during the quarter. Bank of New Hampshire’s holdings in Danaher were worth $1,130,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher during the 3rd quarter valued at about $40,000. FSA Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $50,000. Darwin Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $55,000. Finally, Modus Advisors LLC purchased a new position in Danaher during the 4th quarter valued at about $56,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock traded up $4.27 during trading on Tuesday, reaching $242.47. The company had a trading volume of 210,212 shares, compared to its average volume of 2,244,948. The firm has a 50-day simple moving average of $236.25 and a 200-day simple moving average of $254.22. The company has a market cap of $175.13 billion, a price-to-earnings ratio of 46.27, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business posted $2.02 EPS. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

A number of research analysts have commented on DHR shares. Royal Bank of Canada cut their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. UBS Group cut their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Barclays cut their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Finally, Robert W. Baird cut their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.